Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from Brokerages

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.67.IMUX has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. William Blair initiated coverage on shares of Immunic in a report on Tuesday. They set an "outperform" rating on the stock. D. Boral Capital reissued a "buy" rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th.View Our Latest Analysis on ImmunicImmunic Trading Up 3.3 %Shares of Immunic stock opened at $1.24 on Friday. The firm has a market capitalization of $111.70 million, a PE ratio of -1.01 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The business's 50-day moving average price is $1.08 and its 200-day moving average price is $1.21. Hedge Funds Weigh In On ImmunicA number of hedge funds have recently modified their holdings of IMUX. Jane Street Group LLC grew its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth approximately $81,000. State Street Corp grew its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 51.82% of the company's stock. Immunic Company Profile (Get Free ReportImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.Further ReadingFive stocks we like better than ImmunicP/E Ratio Calculation: How to Assess StocksPenny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell Dividend Capture Strategy: What You Need to KnowTop 3 Beverage Stocks Pouring Out ProfitsESG Stocks, What Investors Should KnowCarMax and Carvana: Steering the Used Car MarketThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Immunic Right Now?Before you consider Immunic, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here